

D6.5 Patient event

PRISM 2 – GA 101034377 Psychiatric Ratings using Intermediate Stratified Markers 2

WP 6 - Dissemination, communication, exploitation and training

Lead contributor	Martien Kas (1 – RUG)
	m.j.h.kas@rug.nl
Other contributors	Juliane Dittrich (09 – concentris)

Due date	30.11.2024
Delivery date	30.11.2024
Deliverable type	R
Dissemination level	PU

Description of Work	Version	Date
	V1	21.03.2024

Document History

Version	Date	Description
V1.	14/11/2024	Draft version
V1.	17/11/2024	Comments and internal check
V2.	18/11/2024	Final version

Publishable Summary

As part of PRISM2, two main patient events were organised, and one presentation was given at the Brain Innovation Days, where patient organisation participated. First, as part of the EMA qualification procedure in WP5, we organized together with GAMIAN two patient listening sessions related to social function and the use of digital technologies for assessing social functioning. In total, 17 patients participated in these sessions, and a summary report was generated by GAMIAN highlighting the importance of social functioning for individuals with a mental health condition. Secondly, PRISM2 was presented at the annual EUFAMI congress in 2024. At that meeting, the concept, findings, and implications of the transdiagnostic study performed in PRISM was presented and discussed with patients and patient family members during the congress. Finally, at the Brain Innovation Days 2024 in Brussels, Prof. Kas explained to a variety of stakeholders (including patient and representatives from patient organisation) the importance of transdiagnostic studies to better define mental health diagnosis and develop more effective treatments.

1. Patient listening sessions with GAMIAN

We have generated and submitted an EMA package for the initiation of the qualification procedure for a digital endpoint for social functioning. For that purpose, and in close collaboration with RUG, two patient listening sessions were organized and chaired by the patient organisation GAMIAN. GAMIAN also generated an outcome report from the two patient listening sessions, which was added as an appendix to the EMA package that was submitted. A total of 17 participants took part in the workshops.

As part of WP5, we have coordinated a dialogue process with all the relevant stakeholders to seek support and guidance throughout the BEHAPP qualification application process.

2. Patient event at the EUFAMI conference

EUFAMI congress 2024: June 21-22, approx. 100 participants


Gerry Dawson (PRISM project partner P1Vital) presented the PRISM project outline, findings and implications at the annual EUFAMI congress in Lithuania.



GA 101034377 PRISM 2 – D6.5

3. Brain Innovation Days

At the Brain Innovation Days 2024 in Brussels, Prof. Kas explained to a variety of stakeholders (including patients and representatives from patient organisation) the importance of transdiagnostic studies to better define mental health diagnosis and develop more effective treatments.



Acknowledgement

The PRISM 2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101034377. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Cohen Veterans Bioscience. The information reflects only the authors' views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.